Vita Life SciencesASX:VLS 94 Current Ratio is 2.72 as of Dec. 2025, which is 1% below its 10-year median of 2.75. GuruFocus rates ASX:VLS with a GF Score™ of 94/100 and a GF Value™ of A$2.47 (Fairly Valued). The stock has 1 warning sign investors should review. Among 998 Drug Manufacturers companies, Vita Life Sciences ranks better than 63.53% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Vita Life Sciences's current ratio for the quarter that ended in Dec. 2025 was 2.72.
Vita Life Sciences has a current ratio of 2.72. It generally indicates good short-term financial strength.
The historical rank and industry rank for Vita Life Sciences's Current Ratio or its related term are showing as below:
ASX:VLS'
s Current Ratio Range Over the Past 10 Years
Min: 2.13 Med: 2.75 Max: 4.16
Current: 2.72
During the past 13 years, Vita Life Sciences's highest Current Ratio was 4.16. The lowest was 2.13. And the median was 2.75.
ASX:VLS's Current Ratio is ranked better than 63.53% of 998
companies
in the Drug Manufacturers industry
Industry Median: 1.995
vs ASX:VLS: 2.72
Vita Life Sciences (ASX:VLS) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Vita Life Sciences Current Ratio Related Terms
Vita Life Sciences Current Ratio Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences (ASX:VLS) has a Current Ratio of 2.72 as of Dec. 2025. This is near median its historical median of 2.75. Over the past decade, Vita Life Sciences' Current Ratio has ranged from 2.13 to 4.16. According to the industry distribution chart, Vita Life Sciences ranks #364 out of 998 companies in the Drug Manufacturers industry, placing it in the top 36.5%.
Is Vita Life Sciences' Current Ratio too high?
Vita Life Sciences' current Current Ratio of 2.72 is near median its 10-year median of 2.75. Over the past 10 years, this metric has ranged from a low of 2.13 to a high of 4.16. The Drug Manufacturers industry median Current Ratio is 2.00. Vita Life Sciences' value of 2.72 is 36.3% above this industry median. Based on the distribution chart, Vita Life Sciences ranks #364 out of 998 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vita Life Sciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' Current Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #364 out of 998 companies for Current Ratio. This puts Vita Life Sciences in the upper half of its industry. The industry median Current Ratio is 2.00. Vita Life Sciences' value of 2.72 is 36.3% above this benchmark. Historically, Vita Life Sciences' own Current Ratio has ranged from 2.13 to 4.16 over the past decade. While the company's 10-year median is 2.75 vs. the industry median of 2.00, Vita Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current Current Ratio of 2.72 is 36.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current Current Ratio is 2.72, which is near median its own 10-year median of 2.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.47, compared to a current price of A$2.50 — trading 1.2% above its estimated fair value. The current Current Ratio is 2.72, which is near median its 10-year median of 2.75 and 36.3% above the Drug Manufacturers industry median of 2.00. Vita Life Sciences' overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current Current Ratio is 2.72 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued.
The current stock price of A$2.50 is trading 1.2% above its estimated GF Value™ of A$2.47.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
Current Ratio: 2.72 (near median its 10-year median of 2.75)
GF Value™: A$2.47 vs. price of A$2.50 (1.2% above fair value)
Industry Position: 36.3% above the Drug Manufacturers median (#364 of 998)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
94GF Score
Get the complete analysis for ASX:VLS
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
